{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:41:02Z","timestamp":1784900462842,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41409-025-02564-8","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:16:52Z","timestamp":1744517812000},"page":"864-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25\u2009mg\/kg versus posttransplant cyclophosphamide 50\u2009mg\/kg in patients with acute leukemias"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-4392","authenticated-orcid":false,"given":"Abdullah","family":"Karakus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayfur","family":"Toptas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-2735","authenticated-orcid":false,"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Durdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-8957","authenticated-orcid":false,"given":"Ugur","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Apaydin","family":"Kayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-2367","authenticated-orcid":false,"given":"Ipek Yonal","family":"Hindilerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-5684","authenticated-orcid":false,"given":"Tarik Onur","family":"Tiryaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicle","family":"Iskender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6230-9519","authenticated-orcid":false,"given":"Bahar Uncu","family":"Ulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-8882","authenticated-orcid":false,"given":"Tugce Nur","family":"Yigenoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-663X","authenticated-orcid":false,"given":"Turgay","family":"Ulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-3780","authenticated-orcid":false,"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"key":"2564_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11899-024-00741-y","volume":"19","author":"S Abedin","year":"2024","unstructured":"Abedin S, Hamadani M. Contemporary updates in the prevention and treatment of graft-versus-host disease. Curr Hematol Malig Rep. 2024;19:246\u201355. https:\/\/doi.org\/10.1007\/s11899-024-00741-y","journal-title":"Curr Hematol Malig Rep"},{"key":"2564_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150\u201363. https:\/\/doi.org\/10.1016\/j.bbmt.2012.04.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2564_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","volume":"158","author":"FL Dignan","year":"2012","unstructured":"Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Haemato-oncology task force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30\u201345. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09129.x","journal-title":"Br J Haematol"},{"key":"2564_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5045\/kjh.2011.46.2.80","volume":"46","author":"CK Min","year":"2011","unstructured":"Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol. 2011;46:80\u20137. https:\/\/doi.org\/10.5045\/kjh.2011.46.2.80","journal-title":"Korean J Hematol"},{"key":"2564_CR5","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668 https:\/\/doi.org\/10.3389\/fimmu.2019.02668","journal-title":"Front Immunol"},{"key":"2564_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02580-w","volume":"15","author":"M Ibrahim","year":"2021","unstructured":"Ibrahim M, Bhyravabhotla K, Khalaf B, Van Meter K, Saba NS, Safah H, et al. The utility of hyperbaric oxygen therapy in post-transplant cyclophosphamide-induced hemorrhagic cystitis: a case report and review of the literature. J Med Case Rep. 2021;15:1 https:\/\/doi.org\/10.1186\/s13256-020-02580-w","journal-title":"J Med Case Rep"},{"key":"2564_CR7","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/cancers16142567","volume":"16","author":"A Ju\u00e1rez","year":"2024","unstructured":"Ju\u00e1rez A, Salas MQ, Pedraza A, Su\u00e1rez-Lled\u00f3 M, Rodr\u00edguez-Lobato LG, Solano MT, et al. Reduced dose of post-transplant cyclophosphamide with tacrolimus for the prevention of graft-versus-host disease in HLA-matched donor peripheral blood stem cell transplants: a prospective pilot study. Cancers. 2024;16:2567 https:\/\/doi.org\/10.3390\/cancers16142567","journal-title":"Cancers"},{"key":"2564_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/tri.12448","volume":"28","author":"R Valdez-Ortiz","year":"2015","unstructured":"Valdez-Ortiz R, Bestard O, Llaud\u00f3 I, Franquesa M, Cerezo G, Torras J, et al. Induction of suppressive allogeneic regulatory T cells via rabbit antithymocyte polyclonal globulin during homeostatic proliferation in rat kidney transplantation. Transplant Int. 2015;28:108\u201319. https:\/\/doi.org\/10.1111\/tri.12448","journal-title":"Transplant Int"},{"key":"2564_CR9","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","volume":"9","author":"R Admiraal","year":"2022","unstructured":"Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9:e111\u2013e120. https:\/\/doi.org\/10.1016\/S2352-3026(21)00375-6","journal-title":"Lancet Haematol"},{"key":"2564_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bjh.16355","volume":"188","author":"J Loke","year":"2020","unstructured":"Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188:129\u201346. https:\/\/doi.org\/10.1111\/bjh.16355","journal-title":"Br J Haematol"},{"key":"2564_CR11","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147\u2013e159. https:\/\/doi.org\/10.1016\/S2352-3026(23)00342-3","journal-title":"Lancet Haematol"},{"key":"2564_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403936","volume":"15","author":"H Nakamae","year":"2024","unstructured":"Nakamae H. Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation. Front Immunol. 2024;15:1403936 https:\/\/doi.org\/10.3389\/fimmu.2024.1403936","journal-title":"Front Immunol"},{"key":"2564_CR13","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood.2020009362","volume":"137","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137:3291\u2013305. https:\/\/doi.org\/10.1182\/blood.2020009362","journal-title":"Blood"},{"key":"2564_CR14","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1182\/bloodadvances.2021004192","volume":"5","author":"MM Al Malki","year":"2021","unstructured":"Al Malki MM, Tsai NC, Palmer J, Mokhtari S, Tsai W, Cao T, et al. Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Adv. 2021;5:2650\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2021004192","journal-title":"Blood Adv"},{"key":"2564_CR15","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/bmt.2017.83","volume":"52","author":"YS Jethava","year":"2017","unstructured":"Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transplant. 2017;52:1504\u201311. https:\/\/doi.org\/10.1038\/bmt.2017.83","journal-title":"Bone Marrow Transplant"},{"key":"2564_CR16","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114\u201325. https:\/\/doi.org\/10.1038\/s41409-020-0803-y. Erratum in: Bone Marrow Transplant. 2020; 55(6): 1213 10.1038\/s41409-020-0835-3","journal-title":"Bone Marrow Transplant."},{"key":"2564_CR17","doi-asserted-by":"publisher","first-page":"780.e1","DOI":"10.1016\/j.jtct.2021.05.020","volume":"27","author":"G Llaurador","year":"2021","unstructured":"Llaurador G, Nicoletti E, Prockop SE, Hsu S, Fuller K, Mauguen A, et al. Donor-host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: influence of pretransplantation variables and correlation with post-transplantation outcomes. Transplant Cell Ther. 2021;27:780.e1\u2013780.e14. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.020","journal-title":"Transplant Cell Ther"},{"key":"2564_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"May","key":"2564_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-020-0804-2","volume":"34","author":"F Malard","year":"2020","unstructured":"Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34(May):1229\u201340. https:\/\/doi.org\/10.1038\/s41375-020-0804-2","journal-title":"Leukemia"},{"key":"2564_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"2564_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2307\/2531021","volume":"39","author":"DA Schoenfeld","year":"1983","unstructured":"Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499\u2013503.","journal-title":"Biometrics"},{"key":"2564_CR22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Y Zu","year":"2022","unstructured":"Zu Y, Li Z, Gui R, Liu Y, Zhang Y, Yu F, et al. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10\/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Bone Marrow Transplant. 2022;57:1573\u201380. https:\/\/doi.org\/10.1038\/s41409-022-01754-y","journal-title":"Bone Marrow Transplant"},{"key":"2564_CR23","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull. 2021;66:2498\u2013505. https:\/\/doi.org\/10.1016\/j.scib.2021.06.002","journal-title":"Sci Bull"},{"key":"2564_CR24","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","volume":"94","author":"J Tischer","year":"2015","unstructured":"Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94:1677\u201388. https:\/\/doi.org\/10.1007\/s00277-015-2423-y","journal-title":"Ann Hematol"},{"key":"2564_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","volume":"58","author":"R Dul\u00e9ry","year":"2023","unstructured":"Dul\u00e9ry R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2023;58:386\u201392. https:\/\/doi.org\/10.1038\/s41409-022-01908-y","journal-title":"Bone Marrow Transplant"},{"key":"2564_CR26","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00277-024-05724-w","volume":"103","author":"Z Tian","year":"2024","unstructured":"Tian Z, Man Q, Yang Y, Guan H, Wang Y, Luo R, et al. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2024;103:1729\u201336. https:\/\/doi.org\/10.1007\/s00277-024-05724-w","journal-title":"Ann Hematol"},{"key":"2564_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bmt.2014.296","volume":"50","author":"TR Spitzer","year":"2015","unstructured":"Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469\u201375. https:\/\/doi.org\/10.1038\/bmt.2014.296","journal-title":"Bone Marrow Transplant"},{"key":"2564_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ejh.13230","volume":"102","author":"S Prem","year":"2019","unstructured":"Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, et al. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. Eur J Haematol. 2019;102:486\u201393. https:\/\/doi.org\/10.1111\/ejh.13230","journal-title":"Eur J Haematol"},{"key":"2564_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41409-018-0382-3","volume":"54","author":"J Yang","year":"2019","unstructured":"Yang J, Jiang J, Cai Y, Li S, Wan L, Zhu J, Liu H, et al. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplant. 2019;54:1049\u201357. https:\/\/doi.org\/10.1038\/s41409-018-0382-3","journal-title":"Bone Marrow Transplant"},{"key":"2564_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"W Zhang","year":"2023","unstructured":"Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. Br J Haematol. 2023;200:210\u201321. https:\/\/doi.org\/10.1111\/bjh.18483","journal-title":"Br J Haematol"},{"key":"2564_CR31","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/jcm11041106","volume":"11","author":"E Xue","year":"2022","unstructured":"Xue E, Lorentino F, Lupo Stanghellini MT, Giglio F, Piemontese S, Clerici DT, et al. Addition of a single low dose of anti T-lymphocyte globulin to post-transplant cyclophosphamide after allogeneic hematopoietic stem cell transplant: a pilot study. J Clin Med. 2022;11:1106 https:\/\/doi.org\/10.3390\/jcm11041106","journal-title":"J Clin Med"},{"key":"2564_CR32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938\u201347. https:\/\/doi.org\/10.1182\/blood-2015-09-671834","journal-title":"Blood"},{"key":"2564_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033\u201340. https:\/\/doi.org\/10.1182\/blood-2015-04-639831","journal-title":"Blood"},{"key":"2564_CR34","doi-asserted-by":"publisher","first-page":"313.e1","DOI":"10.1016\/j.jtct.2023.01.009","volume":"29","author":"J Marco-Ayala","year":"2023","unstructured":"Marco-Ayala J, Sanz J, G\u00f3mez-Segu\u00ed I, Balaguer-Rosello A, Montoro J, Guerreiro M, et al. Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation. Transplant Cell Ther. 2023;29:313.e1\u2013313.e10. https:\/\/doi.org\/10.1016\/j.jtct.2023.01.009","journal-title":"Transplant Cell Ther"},{"key":"2564_CR35","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1182\/bloodadvances.2023009791","volume":"7","author":"K Maurer","year":"2023","unstructured":"Maurer K, Ho VT, Inyang E, Cutler C, Koreth J, Shapiro RM, et al. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023;7:3903\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2023009791","journal-title":"Blood Adv"},{"key":"2564_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2313357","volume":"29","author":"MM Gallardo-P\u00e9rez","year":"2024","unstructured":"Gallardo-P\u00e9rez MM, Guti\u00e9rrez-Aguirre CH, Olivares-Gazca JC, Ruiz-Arg\u00fcelles GJ. More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? Hematology. 2024;29:2313357 https:\/\/doi.org\/10.1080\/16078454.2024.2313357","journal-title":"Hematology"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02564-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02564-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02564-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:18:35Z","timestamp":1749543515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02564-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2564"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02564-8","relation":{"is-basis-for":[{"id-type":"doi","id":"10.52843\/cassyni.90jtlx","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}